Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc (APTO) is a clinical-stage biotechnology company pioneering precision therapies for hematologic malignancies. This page serves as the definitive source for verified news and scientific updates related to APTO's innovative oncology pipeline.
Key resources include: Press releases on clinical trial progress, regulatory milestones, partnership announcements with pharmaceutical collaborators, and analyses of treatment mechanisms. Investors will find essential updates on the company's small molecule inhibitors and combination therapy developments targeting AML and high-risk MDS.
Our news collection enables: Tracking of APTO's progress in genetic-guided therapies, monitoring of FDA interactions, and insights into strategic collaborations advancing personalized cancer treatments. Content is curated to meet investor and researcher needs without promotional bias.
Bookmark this page for real-time updates on APTO's scientific advancements and corporate developments. Always consult official filings for investment decisions.
Aptose Biosciences (Nasdaq: APTO; TSX: APS) will announce its financial results for Q1 2021 on May 4, 2021, after market close. The announcement will be followed by a conference call at 4:30 PM ET. Investors can access the call via dial-in or webcast. The Q1 report will include financial statements and management’s discussion available on SEDAR and EDGAR. Aptose focuses on developing therapies for unmet needs in oncology, particularly in hematology, with investigational products luxeptinib and APTO-253 undergoing clinical trials.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference on April 15, 2021, from 3:00 to 3:55 PM EDT. CEO William G. Rice, Ph.D. will join a panel discussing opportunities in BPDCN and AML, moderated by John Newman, Ph.D.
The company focuses on developing personalized therapies for oncology, particularly hematology. Their pipeline includes luxeptinib, a mutation-agnostic FLT3/BTK inhibitor, and APTO-253, which targets the MYC oncogene.
Aptose Biosciences Inc. (NASDAQ: APTO) reported a net loss of $14.7 million for Q4 2020, increasing to $55.2 million for the full year, attributed mainly to higher R&D and stock-based compensation expenses. The company continues to progress in its clinical trials for luxeptinib and APTO-253, with encouraging early signs of anti-cancer activity. Additionally, CFO Gregory Chow is resigning, with Dr. William Rice taking over as Chief Accounting Officer. As of December 31, 2020, Aptose had $122.4 million in cash, sufficient to support operations through mid-2023.
Aptose Biosciences announces key management appointments to enhance clinical development and regulatory functions. George Melko, Pharm.D., joins as Vice President of Regulatory Affairs, bringing over 20 years of oncology regulatory experience from companies like Tmunity and Incyte. Robert Killion, Ph.D., appointed Vice President of CMC, has over 20 years in manufacturing and quality control from firms such as Gilead and Roche. These hires aim to support ongoing Phase 1 trials of CG-806 and APTO-253, reinforcing Aptose's commitment to advancing innovative cancer therapies.
Aptose Biosciences Inc. (Nasdaq: APTO) will release its financial results for the year and quarter ended December 31, 2020, on March 23, 2021, after market close. The company is focused on developing therapeutics targeting cancer mechanisms, particularly in hematology. Aptose's clinical pipeline includes CG-806, a first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, and APTO-253, which directly targets the MYC oncogene. Both products are currently in clinical trials.
Aptose Biosciences has initiated dosing of the first patient in a Phase 1 a/b clinical study for CG-806, an oral kinase inhibitor targeting acute myeloid leukemia (AML). The starting dose of 450mg was selected based on previous safety and efficacy data in chronic lymphocytic leukemia (CLL) trials. This multicenter, open-label study aims to evaluate the drug's safety and pharmacodynamics in relapsed or refractory AML patients. The company is also conducting another Phase 1 study for B-cell malignancies.
Aptose Biosciences Inc. (Nasdaq: APTO) announced its participation in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020, at 1:40 PM EDT. The event will feature a fireside chat with Matthew Biegler, Senior Analyst at Oppenheimer. The audio webcast can be accessed via the Aptose website and will be archived post-event. Aptose focuses on developing targeted cancer therapeutics, including CG-806 and APTO-253, currently in clinical trials for hematologic malignancies.
Aptose Biosciences (Nasdaq: APTO; TSX: APS) has announced participation in two upcoming virtual conferences in September 2020. The H. C. Wainwright 22nd Annual Global Investment Conference is scheduled for September 14, 2020, at 2:30 PM EDT, while the Cantor Virtual Global Healthcare Conference will take place on September 17, 2020, at 10:00 AM EDT. The management team, led by Dr. William G. Rice, will present and discuss their innovative oncology therapies targeting hematologic malignancies. Webcasts are available through the Aptose website.
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) announced participation in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Key executives, including Dr. William G. Rice, will present a corporate overview and strategic direction on August 13 at 2:00 p.m. ET. The live presentation can be accessed via Webcast Link, with an archived version available for 90 days on the company's website.
Aptose Biosciences announced advancements in its clinical trials for CG-806 and APTO-253, with progress into higher dose cohorts and FDA approval for CG-806's IND in AML at a 450 mg dose. Financially, the company reported a net loss of $15.8 million for Q2 2020, up from $6.2 million YOY, primarily due to increased stock-based compensation and program costs. Cash and investments totaled $82.7 million, sufficient for operations through 2023. The company recently raised approximately $55.125 million through a public offering of common shares.